January 17, 2017 09:41 AM EST

Upstart maps plans to build fibrosis pipeline; FDA extends review period for Lilly’s baricitinib

Shehla Shakoor

Managing Director

• A group of academic investigators in Toronto, working through MaRS Innovation, are spinning out new tech to launch a biotech startup dubbed Fibrocor …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Upstart maps plans to build fibrosis pipeline; FDA extends review period for Lilly’s baricitinib

Shehla Shakoor

Managing Director

Sign up to read this article for free.

CagriSema’s weight loss data disappointed. What does Novo do next?

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

CMS explains what went into its first round of drug price negotiations

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra

Viatris' India-based manufacturing site blocked from shipping 11 generic drugs to US

Up­start maps plans to build fi­bro­sis pipeline; FDA ex­tends re­view pe­ri­od for Lil­ly’s baric­i­tinib

Shehla Shakoor

Managing Director

Sign up to read this article for free.

more like this

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Vi­a­tris' In­dia-based man­u­fac­tur­ing site blocked from ship­ping 11 gener­ic drugs to US

Upstart maps plans to build fibrosis pipeline; FDA extends review period for Lilly’s baricitinib

CagriSema’s weight loss data disappointed. What does Novo do next?

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

CMS explains what went into its first round of drug price negotiations

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra

Viatris' India-based manufacturing site blocked from shipping 11 generic drugs to US